M&A Advisory

Dan Berenson is a Senior Managing Director focused at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2019, Dan spent the early part of his career at Centerview Partners and Guggenheim Securities where he executed multiple biopharma transactions. Dan has extensive experience advising both public and private biopharma companies on matters involving mergers and acquisitions, asset sales and licensing transactions. During his 15 years as a healthcare M&A professional, he has advised on >30 strategic transactions, including Assertio’s acquisition of Spectrum Pharmaceuticals, Rocket Pharmaceuticals’ acquisition of Renovacor, Zogenix’s sale to UCB, Dermira’s sale to Eli Lilly and Ambit’s sale to Daiichi Sankyo.

He earned an M.B.A. from Yale School of Management and a B.A. from Emory College.

Philip Boyd is a Senior Managing Director in Investment Banking at Leerink Partners, he will help lead M&A efforts across Healthcare Services and Technology as well as support clients in the Healthcare Services Providers space. Phil has advised a wide variety of clients on mergers and acquisitions, divestitures, spin-offs, recapitalizations, leveraged buyouts, takeover defense, and capital raising.

Phil joined the Firm in 2024 from Guggenheim Securities, where he spent nearly a decade in the healthcare services sector, leading efforts to execute strategic transactions involving both public and private companies. Earlier in his career, he was an associate in Citigroup’s Healthcare Investment Banking Group.

He earned his B.S. in Applied Economics and Management and his M.B.A. from Cornell University.

Michael Clifford is a Senior Managing Director in Investment Banking at Leerink Partners covering Healthcare Technology and Services and supporting the Firm’s Mergers & Acquisitions efforts. With more than 13 years of Healthcare Investment Banking experience, he has led efforts to execute strategic transactions for a variety of public and private companies on mergers & acquisitions, equity offerings (IPOs, follow-ons and private placements), acquisition financings and debt financings. Michael joined the Firm in 2015 from Wells Fargo Securities where he worked in the Consumer and Healthcare Investment Banking Group covering Healthcare Technology and Services verticals. Prior to Wells Fargo Securities, he worked in the Transaction Services group at PwC in New York.

He holds a BSBA (cum laude) in Financial Management & Investments and Accounting from the University of Arkansas.

Aniket Kaloti is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2018, Aniket spent nearly 5 years in consulting, most recently at IQVIA, advising biopharma clients on a range of strategic projects spanning corporate finance, brand and commercial strategy, business development and M&A due diligence, and financial analysis. He has advised on a number of biopharma transactions at Leerink Partners including the sale of Decibel to Regeneron, the sale of Zogenix to UCB, and the sale of Dicerna to Novo Nordisk. Earlier in his career, Aniket advised multiple biotech and health-tech startups, including with respect to raising capital through government grants and private investors. Prior to joining the industry, he was a post-doctoral scholar in the Department of Brain and Cognitive Sciences at the Massachusetts Institute of Technology.

He earned his M.B.B.S. (US M.D. Equivalent) from University of Mumbai, Masters’ in Biomedical Engineering at IIT Bombay and PhD in Neuroscience at Northwestern University.

Dan Lepanto is a Senior Managing Director at Leerink Partners and leads the Biopharma Mergers & Acquisitions team.

Prior to joining the firm in 2008, Dan spent 10 years at Cowen and Company where he executed a range of biopharma M&A transactions. Dan began his career in the Mergers & Acquisitions group at Wasserstein Perella. He has advised on a number of biopharma and health care transactions over the span of his career including the sale of Dicerna to Novo Nordisk, the sale of Dermira to Eli Lilly, the sale of NPS to Shire, the sale of Cynosure to Hologic, the sale of TKT to Shire, the sale of GelTex to Genzyme, the merger of Total Renal Care with Renal Treatment Centers and the acquisition of Vivra by Gambro.

He earned his B.S. in Finance with High Honors from Pennsylvania State University.